Skip to main content
TipRanks
Go Ultimate75% OFF

Bicara Therapeutics Inc. (BCAX) Stock Price & Analysis

93 Followers

BCAX Stock Chart & Stats

$9.60-$0.15(-1.54%)
At close: 4:00 PM EST
$10$15$20$25Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$9.34 - $9.92
52-Week Range
$7.87 - $30.99
Previous Close
$9.75
Volume
N/A
Average Volume (3M)
1.81M
Market Cap
$647.28M
Enterprise Value
$831.00M
Total Cash (Recent Filing)
$442.35M
Total Debt (Recent Filing)
$880.00K
Price to Earnings (P/E)
―
Beta
1.71
Next Earnings
Apr 01, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Durable Clinical Efficacy

The reported Phase Ib responses are both deep and durable, with substantial tumor shrinkage and nearly two years of median response duration. If confirmed in the pivotal program, this profile could support meaningful differentiation in HPV-negative head and neck cancer and strengthen the candidate’s clinical positioning.

Pivotal Trial Advancement

Substantial enrollment in the approximately 650-patient pivotal study indicates meaningful clinical execution and moves the program toward an important efficacy readout. The planned interim analysis should provide a more consequential test of whether earlier clinical signals can translate into regulatory and commercial progress.

Funding Runway And Low Leverage

A cash runway extending into the first half of 2029 gives Bicara time to advance its pivotal study, regulatory preparation, manufacturing, and early commercial infrastructure. Minimal debt further reduces fixed financing pressure while the company remains dependent on clinical development rather than product revenue.

Bears Say

Pre-Revenue Loss Profile

Without product revenue, Bicara’s financial performance is determined by research, development, and organizational spending rather than commercial execution. Losses have widened sharply over time, increasing the distance to self-funded operations and making future value increasingly dependent on successful clinical and regulatory outcomes.

Accelerating Cash Burn

The worsening operating and free cash flow profile shows that advancing the pipeline requires substantial ongoing funding. Persistent burn can reduce financial flexibility before revenue begins and may create future reliance on equity financing or other capital, with potential dilution if spending remains elevated.

Pivotal And Regulatory Uncertainty

The pivotal study has not yet produced definitive data, while the filing path and interim overall survival requirements remain uncertain. These unresolved clinical and regulatory questions can delay approval, require additional evidence, or weaken the ability to convert promising Phase Ib results into a reliable development timeline.

Bicara Therapeutics Inc. News

BCAX FAQ

What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $7.87 and its highest was $30.99 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $647.28M.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
Bicara Therapeutics Inc.’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 134 days.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on Nov 09, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.82 by -$0.22.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate is -1.04.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 66,387,200 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.82. Following the earnings report the stock price went up 15.376%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Hedge funds hold Bicara Therapeutics Inc. shares: the largest hedge-fund position in Bicara Therapeutics Inc. is 72,418,511 shares, and hedge funds increased their holdings by 434.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology